The tetraspanins family of membrane glycoproteins are involved in the regulation of cellular development, proliferation, activation and mobility. We have attempted to predict the structural features of the large extracellular domain of tetraspanins (EC2), which is very important in determining their functional specificity. The tetraspanin EC2 is composed of two subdomains: a conserved three helix subdomain and a variable secondary structure subdomain inserted within the conserved subdomain. The occurrence of key disulphide bridges and other invariant residues leads to a conserved relative topology of both subdomains and also suggests a structural classification of tetraspanins. Using the CD81 EC2 structure as a template, the structures of two other EC2s were predicted by homology modelling and indicate a conserved shape in which the variable subdomain located at one side of the structure. The conserved and the variable subdomains might contain sites that correspond respectively to common and specific interactions of tetraspanins. The tetraspanin EC2 appears to correspond to a new scheme of fold conservation/variability among proteins, namely the insertion of a structurally variable subdomain within an otherwise conserved fold.
INTRODUCTION
Tetraspanins are a family of membrane glycoproteins that appear to be involved in various aspects of the regulation of cellular development, proliferation, activation, and mobility. Several recent studies suggest that their role is at least in part mediated by their ability to interact with other proteins such as integrins, coreceptor molecules and MHC antigens as well as other tetraspanins (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Several tetraspanins have also been shown to be involved in binding of specific virus (12) (13) (14) (15) (16) or toxins (17, 19) . Current hypotheses view tetraspanins as "molecular facilitators", the function of which would be to bring into close proximity other proteins involved in cellular processes (for a review see 19) . Such properties might lead to the formation of large membrane complexes of the involved proteins that may be associated with lipid rafts (20) . Tetraspanins are type II proteins, characterized by four transmembrane segments (TM1-4) with both intracytoplasmic N-and C-terminal extremities linked by one short extracellular, one short intracellular, and one large extracellular (EC2) stretches. In addition, to these general features, tetraspanins possess a number of conserved residues in both the intra-and extra-membrane regions. Among these is the socalled « tetraspanin signature » which consists of a specific stretch of residues located in the TM2/intracellular loop/TM3 region. Distant members of the tetraspanin family also exist and share the same transmembrane pattern and many conserved residues but lack the tetraspanin signature. As for "true" tetraspanins, the functions of many tetraspanin-like proteins, such as RDS/ROM proteins or uroplakins, appear to involve self-association and/or association with other proteins (21, 22) .
Some data indicate that part of the specific activity of tetraspanins is determined by the large extracellular EC2 region (23) (24) (25) . Unlike the TM regions that are significantly conserved, this region is highly variable in size and in sequence composition. There are nonetheless a few invariant residues, which include an ubiquitous CCG motif. Recently Kitadokoro et al. (26) have reported that the crystallographic structure of a soluble form of the tetraspanin CD81 EC2 domain is a 5 helix bundle stabilized by 2 disulfide bridges and suggest that key structural features and the protein fold are conserved among tetraspanins. Such an hypothesis must be tested with other tetraspanins, especially in view of the very low conservation and variable size of the EC2 region. Indeed, the central part of the EC2 region (located between the CCG motif and the last canonical cysteine), which in CD81 corresponds to a by guest on January 8, 2018 http://www.jbc.org/ Downloaded from ranging from 24 to 87 residues.
In order to investigate these features in more detail, we have attempted to predict the structure of the tetraspanin EC2 of all tetraspanin and tetraspanin-like proteins using multiple sequence alignments, secondary structure and accessibility prediction methods as well as homology modeling. The predictions obtained for CD81 are in agreement with the experimental structure (26) indicating the reliability of this approach. On the other hand, our data indicate that the structural features of the CD81 EC2 are only partially conserved among tetraspanins. It appears that the EC2 domain corresponds to a structural conservation and variability scheme that is unique among proteins. The EC2 seems to be organized in 2 subdomains. The first subdomain, in spite of significant sequence divergence, appears to have a structurally conserved fold. A second subdomain, with an even higher heterogeneity, is extremely variable in size, secondary structure, and fold. The variable subdomain is inserted within the conserved subdomain and their relative topology is governed by the occurrence of key disulfide bridges the number of which corresponds to distinct subtypes of tetraspanins.
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RESULTS

Sequence conservation and variability of the tetraspanin EC2
The tetraspanin or tetraspanin-like sequences that were retrieved from the SWISSPROT-TREMBL database are indicated in Table I . All sequences had in common: (1) the occurrence of 4 hydrophobic spans of ca. 20-25 residues corresponding to the TM segments, two extracellular loops of unequal size separating TM1-TM2 and TM3-TM4, respectively, and a short intracellular domain between TM2-TM3; (2) a few very highly conserved residues in the second extracellular loop including the CCG motif. The list contains "true" tetraspanins that have in common the tetraspanin signature, as well as distant members.
Apart from the well identified tetraspanin proteins (i.e. the CD's) and well known distant members (RDS, ROM, and UPK), most sequences arise from genomic sequence cDNA translations. Figure 1 shows the multiple sequence alignment of all EC2 domains. Only sequences corresponding to distinct subcategories of a single tetraspanin type or to identical tetraspanins from distinct organisms can be straightforwardly aligned along their entire lengths. Otherwise, sequences have been aligned in order to match several completely or partially conserved residues as well as chemically similar residues.
The only canonical residues are the CCG motif and two other cysteine residues. A motif formed of an aspartic acid or asparagine followed by an aromatic residue occurs in ca. 85% of the sequences. A few residues, mainly cysteines, serines and prolines are conserved between large groups of sequences. The overall homology between different tetraspanins EC2 ranges from 5 to 40% and the average pairwise homology is only 15%. EC2 sequences also vary greatly in length, a feature that introduces large gaps in the alignment. It is mainly the central region of the sequences (i.e. between the conserved CCG and the last conserved cysteine) that varies in length and therefore the corresponding region of the alignment carries the larger gaps. This difference between the side regions and the central region of the alignment also manifests itself in the degree of homology. While a certain extent of homology is apparent in the side regions between particular subgroups of sequences, there is virtually no homology between EC2s from distinct tetraspanin types in the central regions apart from the aforementioned residues (in Figure 1 sequences stretches between conserved residues in this region are aligned for different tetraspanin types only to save space). The number of conserved cysteine residues in the EC2 sequences is variable, being either 4, 6 or 8, a feature which allows the classification of sequences into 3 groups. Various data indicate that the cysteines form disulfide bridges as indicated in figure 1 . The existence of two disulfide by guest on January 8, 2018 http://www.jbc.org/ Downloaded from bridges involving the 4 cysteines conserved in all sequences is documented from the known structure of the CD81 EC2 (26) . Sequences displaying only these 4 cysteines and therefore 2 disulfides correspond to the simplest EC2 type (group 1). From Figure 1 , it is clear however that the majority of EC2 sequences (group 2) possesses an additional pair of cysteines. Disulfide formation by these two latter cysteines appears very likely since it has already been suggested for two members of this group, ROM and RDS, for which their mutation (as well as that of the 4 canonical cysteines) precludes a proper protein insertion (36) . There are actually two subtypes within group 2 depending on the exact position of one cysteine relative to the other. The first additional cysteine of group 2 sequences is found in close proximity to the third canonical cysteine. For the minoritary group 2a sequences, the first additional cysteine is present in a conserved PCSC motif while for the majoritary group 2b sequences, it occurs in a conserved PXSCC motif (while there are several alignment possibilities for these motifs, the presence of conserved serine and proline residues in both group 1 and 2 led us to the proposal in Figure 1 in agreement with (26) . A few tetraspanin EC2 sequences (group 3) contain two more cysteine residues that are relatively close to each other. Since no sequence exists that contain only one of these cysteines, it appears also likely that these form a fourth disulfide bridge although currently no experimental data exist in this regard. In the alignment, gaps occur in all regions separating the conserved cysteine residues.
The experimentally determined secondary structure of the CD81 EC2 (26) is also indicated in Figure 1 .
Interestingly, three of the five helices (A, B and E) correspond to the three non-gapped regions at the sides of the alignment, a feature which suggests the presence of regions of at least conserved size.
These three helices also correspond to the most conserved regions among sequences, specially for helix B. Although the extent of homology per se (i.e. the percentage of identical residues in pairwise alignments) is not significantly higher, there appear to be more conserved residue types. Such conserved residues types in helices A, B and E were already noted in (26) and our data confirm these observations for a larger number of sequences. It appears that 14 specific positions located in all 3 helices are almost invariably occupied by hydrophobic residues. On the other hand, there are only 2 conserved polar positions, both located in helix B, that are occupied by an aspartic acid and a glutamine in most sequences although not in CD81.
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Secondary structure and solvent accessibility of the tetraspanin EC2
The results of secondary structure prediction of the EC2 domains of tetraspanins and tetraspanin-like proteins are shown in Figure 2A . For the sake of clarity, in the case of sequences from different organisms and sequences that present more than 85% homology in EC2, only one member has been reproduced. For homologous sequences or sequence regions, the secondary structure shown in Figure   2A was predicted using a multiple sequence alignment as input for the JPRED consensus method and is therefore valid for all sequences. Such sequences were also examined one by one by the single sequence-oriented NPS method as a control. Consistent results were obtained in the great majority of cases. The NPS method was the sole usable approach for secondary structure determination of those EC2 sequences or sequence regions of Figure 2A that had no homologues in Figure 1 . The recent determination of the three-dimensional structure of the EC2 domain of the tetraspanin CD81 (26) provides us with an opportunity to check the reliability of the prediction methods. The experimental secondary structure found for this domain is also indicated in Figure 2A . It can been seen that the secondary structure prediction for the CD81 EC2, which correspond to the JPRED result, matches quite accurately the 5 actual helices of at a 1-2 residue error level. A similar accuracy is found when the CD82 EC2 sequence is analyzed with the NPS method. This suggests that both methods yield satisfactory results with regard to the secondary structure of tetraspanin EC2's. Figure 2A that a very different situation occurs among the aligned EC2 sequences with regard to the predicted secondary structure for the N-and C-terminal parts on one hand and for the central part on the other hand. On the sides of each sequence, the prediction invariably indicates that the secondary structure elements are the same 3 helices, two on the N-terminal side and one on the Cterminal side. These appear to be conserved in all EC2 domains and also correspond to the first 2 (A, B) and the last experimental helices (E) of the CD81 EC2 domain. It is noteworthy that a similar secondary structure is predicted in spite of the relatively low sequence homology in particular for the first helix.
It is obvious from
Oppositely, for the central region of the EC2 alignment, virtually no conservation of secondary structure occurs among the sequences. As already pointed out, the central region of all EC2 sequences appears to be formed of a limited number of sequence stretches separated by cysteine residues. As shown in by guest on January 8, 2018 http://www.jbc.org/ Downloaded from Figure 2A , not only are these sequence stretches very different in length and without homology but they bear no conserved secondary structure. The secondary structure type present in these sequence stretches (within the current ca. 73 % accuracy of prediction) is mostly coil (indicating that loops often occur between the disulfide-forming cysteines) but also occasionally strands or helices. The number of such disulfide-separated variable secondary structure sequence stretches is respectively 2, 3 and 5 for EC2 sequences from group 1, 2 and 3. For the EC2 of CD81 (group 1), the two sequence stretches forming the variable central region appear to correspond to two helices (termed C and D in ref. 26 ) but this specific motif does not appear to be conserved among tetraspanins. Even for tetraspanins that have a similarly sized EC2 central region and the same number of conserved cysteines than CD81, the predicted secondary structural elements located between these cysteines are not helices.
The results of residue solvent accessibility prediction of the EC2 domain of tetraspanins and tetraspaninlike proteins is shown in Figure 2B for the conserved right and left sides of the sequences. Again the structure of the CD81 EC2 (26) serves as a validation test since the external accessibility, measured for the monomer, is also shown. The prediction appears to be relatively accurate. Figure 2B also indicates that there is an obvious periodicity of the predicted accessibility which is conserved on the alignment.
Moreover, the periodicity is roughly 3-4 residues, a feature that is typical of surface helices. This confirms the structurally conserved helical character of the N-and C-terminal parts of the EC2.
These data indicate that the EC2 domain of tetraspanins possesses two very different subdomains. A first subdomain encompassing the N and C terminal sides of the sequence has a similar size and a conserved secondary structure among all tetraspanins in spite of a limited, but significant, sequence conservation. This secondary structure appears to be composed of three helices. A second central subdomain is extremely variable in size and secondary structure, and bears almost no sequence conservation apart from disulfide-forming cysteines. The occurrence of such conserved disulfides suggests, however, that even the variable domain correspond to an at least partially conserved topology.
Topology of the tetraspanin EC2
From our data and the known structure of the CD81 EC2, it is possible to build general models for the topological organization of the EC2 polypeptide chain. The organization of the three conserved helices in all tetraspanins appears similar to that found in the CD81 EC2 structure. This is first suggested by the by guest on January 8, 2018 http://www.jbc.org/ Downloaded from fact that these 3 helices have similar lengths. Moreover, interactions occurring between these helices are significantly conserved. Indeed, for CD81, interactions occur between the A, B and E helices occur at hydrophobic and charged sidechains located at specific sequence positions (as already pointed out in (26) for the A-E pair). Careful examination of the alignment of Figure 1 indicates that although residues at these positions are variable, the potential for interaction is generally conserved (i.e. by having appropriately paired hydrophobic, hydrogen bonding or charged residues). It is therefore likely that the tetraspanins EC2 general topology is determined by a common core, formed by the 3 conserved helices, and a variable domain whose global topology with respect to the common core is stabilized by 2, 3 or even 4 disulfide bonds as shown on Figure 3 . The minimal topology for EC2 is that of group 1 tetraspanins in which two disulfide bridges determine the topology of a variable domain composed of two peptide stretches of variable secondary structure relative to the conserved domain made of three helices.
In group 2 tetraspanins, the second variable peptide stretch is replaced by a pattern formed by two variable peptide stretches separated by a cysteine which forms a third disulfide bridge that can either crossover, or not, one of the canonical disulfide depending on the subtype (2a or 2b). In group 3 EC2, it is the first variable peptide stretch that is replaced by a disulfide-separated two stretch pattern. Therefore, the chain topology of more complex tetraspanin is built from a basic topology by duplication of specific peptide stretches and disulfide insertion.
Three-dimensional structure of the tetraspanin EC2.
It thus seems that tetraspanins share a conserved structural core made of 3 helices (helices A, B and E of ref. 26) upon which is built a variable subdomain with an overall structure determined by a conserved disulfide linking and a globally conserved chain topology although unconserved secondary structure. It appears also likely that not only the chain topology but also the protein topology in a more general sense (i.e. the relative position of secondary structural elements in space) is conserved. This is strongly suggested by the observation that the structural motifs that determine the overall orientation of the unconserved structural elements of the variable subdomain with respect to each other and to the common core in CD81-EC2 are also conserved among tetraspanins. These motifs, which impose specific orientation constraints to the main chain, include not only the 2 disulfide bridges (the relative orientation of which is constrained by the consecutive character of two of the involved cysteines which have a unique by guest on January 8, 2018 http://www.jbc.org/ Downloaded from backbone conformation) but also two specific residues, a glycine and a proline which in each case are neighbor to a disulfide-linked cysteine and promote specific bends of the main chain as emphasized in (26) for CD81. The invariant character of these residues indicates that the local backbone geometries are conserved among tetraspanins. Furthermore, the CD81 EC2 structure contains two other bends strategically located at the start and at the end of the C helix respectively. It is noteworthy that in the alignment of Figure 1 , the corresponding sequence loci often contain glycine and asparagine or proline residues respectively that are well known to often occur at turns or bents. All these features suggest that the overall orientation of the variable structural elements relative to the conserved subdomain is conserved among tetraspanins. On this basis we have attempted to perform homology modeling of two relatively simple tetraspanins EC2, namely CD53 and Q9V3R4, using the framework of the CD81 EC2 structure. For CD53, which is also a group 1 tetraspanin, the C and D helices of CD81 are replaced by two loops ( Figure 4A , center). In addition, the group 2 tetraspanin Q9V3R4 bears an additional disulfide bridge. This latter protein currently bears no particular functional interest since its role is unknown, its sequence being a cDNA translation from the Drosophila Melanogaster genome. However, this sequence happens to have a striking homology with CD81 in critical parts of the variable subdomain of EC2 (see Figure 1 ), although both sequences correspond to different tetraspanin EC2 groups. In particular, 6 residues neighboring the two extra cysteine residues of Q9V3R4 are also found in CD81 at similar sequence positions. Furthermore, the two CD81 residues that are replaced by the disulfide-forming extra cysteines in Q9V3R4, according to the corresponding pairwise alignment (see Figure 1 ), have spatially close and facing sidechains in the X-ray structure (26) . This suggests that these can be used as templates for homology modeling of the extra disulfide bridge. The resulting modeled structure is shown on Figure 4A (right). It is likely that all group 2 tetraspanins have a similar disulfide topology. It should be stressed that the modeling of peptide loops of more than 5-6 residues is currently only approximate (33) so that the modeled structures of Figure 4A may certainly be subject to future improvement. Homology modeling of more complex tetraspanins requires further prediction or experimental work to be performed since it depends upon the tertiary interactions of the extra secondary structural elements. ( Figure 4B ). In spite of the secondary structure differences, the three domains have a similar shape in which the variable subdomain has a specific location. Interestingly, for CD53 the variable region is located relatively close to two glycosylation sites. One of these sites is conserved among a large number of tetraspanin (CD63, CD82, CD151, UPKB, TSP3, TSP6, net6, Q9U3V4, O96961) and is very exposed at the extremity of the first helix (note that this locus in the structure also corresponds in RDS and ROM to a cysteine residue responsible for the functionally important covalent dimer formation in rod outer segment disc membranes) (36) . The other potential glycosylation site also represented for CD53 in Figure 4B is located downstream the conserved CCG motif and also relatively conserved (CD53, CD63, CD82, CD151, TSP3, A15, RDS, NET1, Q9QZA6). A third potential glycosylation site not present in CD53 is often present 6-15 residues upstream from helix E (see Figure 1 ). In all three structures of Figure 4B , the variable domain is located on one side of the EC2 domain which is opposite to an hydrophobic patch conserved in many sequences and which was suggested in (26) to be involved in interactions between tetraspanins. On the other hand, another hydrophobic patch found in the structure of the CD81 EC2 (26) and located in the variable subdomain is not conserved in CD53 and Q9V3R4, in which the residues of this region are relatively hydrophilic. Therefore, this latter hydrophobic patch is specific to CD81. In the corresponding region, both CD53 and Q9V3R4 display an aspartic acid residue (not shown) conserved in almost all tetraspanin that may be involved in specific recognition processes.
DISCUSSION
Our data indicate that all EC2 domains of the tetraspanin superfamily are formed of two subdomains: one conserved and one variable. The conserved subdomain is made of a three helix bundle, corresponding respectively to the two first helices (A and B) and the last helix (E) of the CD81 crystallographic data (26) . The variable subdomain corresponds to a sequence insertion within the conserved three helix bundle subdomain. It differs from one tetraspanin to the other in length and secondary structure and contains only a few conserved residues. The relative topology of the conserved and variable domains is likely to be conserved and corresponds to a bipolarity of the EC2 domain. These data imply that the protein fold found by Kitadokoro et al. (26) for the CD81 EC2 is not conserved among tetraspanins, but that only a "subfold", corresponding to the three helix bundle, is conserved.
It is tempting to suggest that the two subdomains correspond to distinct interaction potentialities of tetraspanins. The conserved subdomain might contain sites that correspond to interactions that are common to all tetraspanins, e.g. interactions with themselves and other tetraspanins, as already suggested for CD81 (26) , as well as with integrins (Serru et al., 1999) . Oppositely, the variable subdomain might promote interactions with proteins that are specific to each tetraspanin, like specific interactions with virus or toxins. Indeed, Higginbottom et al. (23) have mapped the binding site of HCV on CD81 at the end of this variable domain. This does not preclude the possibility that a binding site for a particular protein might involve both subdomain. In this regard, recent data (25) indicate that the interaction between CD151 and α3β1 integrins involve an epitope of the CD151 EC2 (residues 186-217) which overlaps both the end of the variable region (i.e. immediately downstream the third cysteine of group 2 tetraspanins) and the terminal helix of the conserved subdomain. Since, among tetraspanins, our conclusions on the EC2 domain structure. However, circular dichroism quantification of the secondary structure of several soluble EC2s would constitute a simpler structural approach. Another functionnally relevant approach would be the construction of chimeras in which the variable subdomain of EC2 is swapped between distinct tetraspanin types. One might expect that in such chimeras, the functional aspects that involve interactions common to all tetraspanins will be retained. By contrast, those that are related to type-spectific interactions would be swapped accordingly.
In a recent tetraspanin conference (First International Meeting on Tetraspanin Proteins, FASEB Conference, Aspen, July 2000), the need for a classification of tetraspanins was expressed. We suggest that the distinction of the structural groups made here may form one of the bases of this classification.
The occurrence of distinct domains within a protein or a protein family is a rather common feature. In particular, "insertion domains" have been evidenced during the last few years (38) . The most popular of these are the so-called "protein modules" (39) that confer specific interaction potentialities to a number of proteins (as may do the EC2 to tetraspanins). These correspond to domains with relatively variable sequence but with a conserved protein fold. The occurrence of variable sequence segments within a protein family has also been widely documented for immunoglobulins (the "hypervariable loops" (40) or olfactory receptors (41). Again, these correspond to variable sequence stretches within a conserved structural fold. To our knowledge, the tetraspanin EC2 corresponds to a new domain insertion and variability scheme, namely the occurrence of a domain with variable structure within an otherwise conserved fold for a protein family.
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